China's Top Departments: Respiratory and Critical Care Medicine at Shanghai Chest Hospital
A Shanghai Municipal Clinical Key Specialty and one of China's largest single-disease lung cancer diagnosis and treatment bases. Led trials that brought four new drugs to market in five years (including Anlotinib and Penpulimab), with 50,000 hospitalizations and 200,000+ outpatient visits annually, and research published in The Lancet Respiratory Medicine (2024).
What matters most on this page
Short answer:A Shanghai Municipal Clinical Key Specialty and one of China's largest single-disease lung cancer diagnosis and treatment bases. Led trials that brought four new drugs to market in five years (including Anlotinib and Penpulimab), with 50,000 hospitalizations and 200,000+ outpatient visits annually, and research published in The Lancet Respiratory Medicine (2024).
Key points
- One of China's Largest Single-Disease Lung Cancer Bases
- 4 New Drugs to Market in 5 Years (Anlotinib, Penpulimab…)
- 200,000+ Outpatient Visits · 50,000 Hospitalizations Annually
- Published in The Lancet Respiratory Medicine (2024)
If you or a loved one is facing lung cancer, pulmonary nodules, or a severe respiratory condition requiring intensive care, the Department of Respiratory and Critical Care Medicine at Shanghai Chest Hospital is one of China's most experienced centers for lung cancer diagnosis, treatment, and research.
Shanghai Chest Hospital (also known as Shanghai Jiao Tong University School of Medicine Affiliated Chest Hospital) was founded in 1957 as one of China's earliest tertiary (Grade 3A) specialized hospitals focusing on diseases of the heart, lungs, esophagus, trachea and mediastinum. In 1957 it was designated by the Ministry of Health as a national cardiothoracic surgery training base; in 1984 it established China's first lung cancer research center; in 2005 it became an affiliated hospital of Shanghai Jiao Tong University. The current president is Hou Xumin.
The Department of Respiratory and Critical Care Medicine is a Shanghai Municipal Clinical Key Specialty and a key discipline of Shanghai Jiao Tong University. It is positioned as one of China's largest single-disease lung cancer diagnosis and treatment bases, with core strengths in early lung cancer screening and diagnosis, together with precision and whole-course management of advanced lung cancer.
At Medora, we help international patients navigate this team. Here's what you need to know.
Accreditation and Status
- Shanghai Municipal Clinical Key Specialty
- Key discipline of Shanghai Jiao Tong University
- One of China's largest single-disease lung cancer diagnosis and treatment bases
- The hospital established China's first lung cancer research center (1984)
- 172 research hospital beds for clinical studies
Scale and Volume
| Metric | Data |
|---|---|
| Annual hospitalizations | 50,000 |
| Annual outpatient visits | Over 200,000 |
| Research hospital beds | 172 |
| Clinical studies currently ongoing | More than 30 |
Core Strengths
1. Lung Cancer Clinical Research and Drug Development
As a national drug clinical trial base, the department has led clinical trials that brought four new drugs to market in the past five years:
- Anlotinib — China's first multi-target anti-angiogenic drug
- Andacare — a bevacizumab biosimilar
- Micellar paclitaxel — a novel chemotherapeutic
- Penpulimab — a novel immune checkpoint inhibitor
More than 30 clinical studies are currently ongoing.
2. Early Lung Cancer Screening and Diagnosis
A national leader in early lung cancer screening, including electromagnetic navigation bronchoscopy and radiofrequency ablation for minimally invasive diagnosis and treatment.
3. Precision and Whole-Course Management of Advanced Lung Cancer
Driver-gene-guided targeted therapy, immunotherapy, anti-angiogenesis and chemotherapy delivered in a coordinated, whole-course framework.
4. Representative Achievements
The AK105-302 trial (penpulimab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer), co-led by Prof. Han Baohui and Prof. Jiao Shunchang of PLA General Hospital, was published in The Lancet Respiratory Medicine in February 2024. A "chemo-free" first-line strategy combining an immune checkpoint inhibitor with an anti-angiogenic agent was published in Cancer Communications (IF 20.1).
Expert Team
| Expert | Role | Specialty |
|---|---|---|
| Prof. Han Baohui | Department founder and honorary director, vice leader of the Lung Cancer Group of the Chinese Medical Association Respiratory Disease Branch | Over 40 years of clinical research in lung cancer; pioneered driver-gene-guided targeted therapy for lung cancer in China |
| Prof. Zhong Hua | Current department director | Comprehensive lung cancer treatment (chemotherapy, targeted therapy, immunotherapy, anti-angiogenesis) and whole-course management |
| Prof. Chu Tianqing | Chief physician and director of the Clinical Research Center | Lung cancer clinical research and new drug development |
| Dr. Zhang Jie | Director of the Respiratory Endoscopy Center | Bronchoscopic interventional procedures (airway stenting, tumor ablation) |
| Dr. Sun Jiayuan | Expert in early lung cancer diagnosis | Minimally invasive treatment (electromagnetic navigation bronchoscopy, radiofrequency ablation) |
| Specialists (additional) | — | Shi Huanzhong, Li Zhiqiang, Chen Gang, Gu Aiqin and Guo Zhongliang cover respiratory critical care, pulmonary nodules, interstitial lung disease and chronic airway diseases |
Patient Information
Shanghai Chest Hospital No. 241 Huaihai West Road, Xuhui District, Shanghai
- Hospital level: Class III Grade A (tertiary) specialized hospital
Shanghai is China's largest city and an international hub with extensive worldwide flight connections. Most international patients fly into Shanghai Pudong International Airport (PVG) or Shanghai Hongqiao International Airport (SHA).
This guide is prepared for international patients facing lung cancer and respiratory conditions. If you need assistance with medical consultation, appointment booking, or travel arrangements to the Department of Respiratory and Critical Care Medicine at Shanghai Chest Hospital, contact Medora for personalized support.
Need personalized hospital recommendations?
Turn this research into an action plan: get tailored hospital recommendations matched to your condition, budget, and timeline.
✓ Free consultation · Response within 24 hours · 100+ international patients served